Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Bellerophon Shares Take Off as FDA Grants Emergency Expanded Access for INOpulse for COVID-19 ...

Bellerophon Shares Take Off as FDA Grants Emergency Expanded Access for INOpulse for COVID-19 Treatment Shares of Bellerophon Therapeutics reached a new 52-week high price after the firm reported that the FDA granted emergency expanded access for its INOpulse®...
Streetwise Reports | March 23, 2020 |

Savara Shares Double After FDA Grants Breakthrough Therapy Status for aPAP Treatment

Shares of Savara opened nearly 140% higher today after the orphan lung disease company advised that the FDA has granted Breakthrough Therapy designation for the firm's Molgradex for treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP). This morning orphan lun...
Streetwise Reports | January 2, 2020 |

FDA Grants Ampio Pharma Approval to Begin Phase 1 Trial in COVID-19 Patients

Ampio Pharmaceuticals' shares traded higher after the company reported that the FDA cleared the firm to proceed with human trials of its Investigative New Drug application for intravenous AmpionTM for treatment in COVID-19 affected patients on supplemental oxygen. ...
Streetwise Reports | June 22, 2020 |

CytoSorbents Shares Trade 20% Higher as FDA Grants CytoSorb EUA for COVID-19

Shares of CytoSorbents traded higher setting a new 52-week intraday high price after the company reported that the FDA granted emergency use authorization for CytoSorb for use in patients with COVID-19. Critical care immunotherapy company CytoSorbents Corp....
Streetwise Reports | April 14, 2020 |

BioNTech, Eastman Kodak, EXMceuticals - investors have the chance to profit

The importance of health has not been as clear for a long time as it was in 2020. Detached from the discussion about the specifics of COVID-19 on mortality compared to other viruses, the need for protection is great and helplessness without a medical response is harmful to the...
Mario Hose | July 29, 2020 |

BioNTech, CureVac, EXMceuticals - reaching their goal with government support

In the fight against the spread of the Corona Pandemic, a great deal of commitment is required from companies. This situation also offers the opportunity to rethink and change existing work processes and procedures. Product ranges are being expanded and new possibilities and a...
Mario Hose | September 18, 2020 |

Equity Metals focuses on discovery in British Columbia

Equity Metals Corp. (TSXV:EQTY) is a Canada-based mineral exploration company. The company owns 100 per cent interest, with no underlying royalties, in its flagship Silver Queen Project along the Skeena Arch in the Omineca Mining Division in British Columbia. Equ...
Coreena Robertson | September 19, 2023 |

Intercept Pharma Shares Rise on FDA Acceptance of NDA for Liver Fibrosis Treatment

Shares of Intercept Pharmaceuticals rose today after the company reported that the U.S. Food and Drug Administration accepted its NDA for obeticholic acid (OCA) for the treatment of liver fibrosis due to NASH and granted priority review status. This morning biopharmac...
Streetwise Reports | November 27, 2019 |

Immuno-Oncology Firm Expands Agreement with AbbVie

The revisions to the existing arrangement between the two U.S. firms are discussed in a ROTH Capital Partners report. In a Nov. 21 research note, ROTH Capital Partners analyst Zegbeh Jallah reported that Harpoon Therapeutics Inc. (HARP:NASDAQ) and AbbVie Inc. (ABBV...
Streetwise Reports | December 5, 2019 |

Could the US Become Another Weimar Republic?

Rudi Fronk and Jim Anthony, cofounders of Seabridge Gold, discuss the potential ramifications of current U.S. fiscal and monetary policy. The U.S. monetary and fiscal authorities are shoveling trillions of dollars into the U.S. economy to prevent a collapse ...
Streetwise Reports | March 31, 2020 |
1 2 3